Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Basic) (2019 - 2025)

Cyclerion Therapeutics has reported EPS (Basic) over the past 6 years, most recently at -$0.34 for Q3 2025.

  • Quarterly results put EPS (Basic) at -$0.34 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was -$1.5 (changed N/A YoY), and the annual figure for FY2023 was $3.14, up 410.41%.
  • EPS (Basic) for Q3 2025 was -$0.34 at Cyclerion Therapeutics, up from -$0.59 in the prior quarter.
  • Over the last five years, EPS (Basic) for CYCN hit a ceiling of $5.53 in Q3 2023 and a floor of -$6.16 in Q2 2022.
  • Median EPS (Basic) over the past 4 years was -$0.32 (2022), compared with a mean of -$0.44.
  • Biggest five-year swings in EPS (Basic): plummeted 1268.89% in 2022 and later soared 2405.61% in 2023.
  • Cyclerion Therapeutics' EPS (Basic) stood at -$0.24 in 2021, then surged by 33.33% to -$0.16 in 2022, then soared by 3558.42% to $5.53 in 2023, then plummeted by 106.12% to -$0.34 in 2025.
  • The last three reported values for EPS (Basic) were -$0.34 (Q3 2025), -$0.59 (Q2 2025), and -$0.57 (Q1 2025) per Business Quant data.